SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* KISNER DANIEL L (Last) (First) (Middle) C/O TEKMIRA PHARMACEUTICALS CORP. SUITE 100, 8900 GLENLYON PARKWAY (Street) BURNABY A1 V5J 5J8 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/01/2015	3. Issuer Name and Ticker or Trading Symbol TEKMIRA PHARMACEUTICALS Corp [ TKMR ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	12,500	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	01/28/2010	01/27/2020	Common Shares	10,000	3.85(1)	D
Director Stock Option (Right to Buy)	08/10/2011	08/09/2021	Common Shares	5,000	2.4(1)	D
Director Stock Option (Right to Buy)	12/27/2011	12/22/2021	Common Shares	5,000	1.7(1)	D
Director Stock Option (Right to Buy)	12/10/2012	12/09/2022	Common Shares	5,000	5.15(1)	D
Director Stock Option (Right to Buy)	05/08/2014	05/07/2024	Common Shares	17,500	12.52(1)	D
Warrants	06/16/2011	06/16/2016	Common Shares	5,000	3.35(1)	D
Warrants	02/29/2012	03/01/2017	Common Shares	1,250	2.6(1)	D

Explanation of Responses:

1. Expressed in Canadian dollars.

Remarks:

	/s/ Daniel L. Kisner	12/31/2014
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.